“Radioimmunotherapy of prostate cancer.”
Quarterly Journal of Nuclear Medicine and Molecular Imaging. 2004 Dec;48(4):297-304.
This is a review of recent advances in the treatment of metastatic prostate cancer with radiopharmaceuticals, specifically those undergoing clinical evaluation. The emerging (177)Lu radionuclide is compared with Zevalin (90)Y-ibritumomab and Bexxar (131)I-tositumomab. The current cornerstone therapy for metastatic prostate cancer is hormonal therapy. The areas where prostate cancer is known to metastasize are the lymph nodes and bone marrow. These sites are readily accessible to circulating monoclonal antibodies. This review also discusses radioimmunotherapy as an alternative to hormonal therapy with several antigens showing promising results.